CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 456 enrolled
Drug / intervention
Hydroxychloroquine +3 moredrug
Likely dose
Hydroxychloroquine 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04349592
NCT04349592N/ACompleted
CompareCT.gov

Randomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19

Hamad Medical Corporation·interventional·Posted Apr 16, 2020·Updated Feb 23, 2021

In Brief

A clinical study evaluating Hydroxychloroquine, Azithromycin, and 2 other interventions for Covid19. Completed, enrolled 456 participants across 1 site.

Detailed Summary

Q-PROTECT is a placebo controlled randomized trial (RCT) to ascertain the efficacy of hydroxychloroquine (HC) alone or, in combination with azithromycin (AZ), in reducing viral load in patients with COVID 19.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesQatar
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedApr 16, 2020
Enrollment StartApr 14, 2020
Primary CompletionAug 14, 2020
Study CompletionAug 30, 2020
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.2 years ago

Interventions

Hydroxychloroquinedrug

Hydroxychloroquine 200 mg tablet oral, one tablet three times a day for 7 days

Azithromycindrug

Azithromycin 250 mg capsules oral, 2 capsules on day one, followed by 1 capsule once a day for days 2-5.

Placebo Tabletother

Oral, one tablet three times a day for 7 days

Placebo capsulesother

Oral 2 capsules on day one, followed by 1 capsule once a day for days 2-5.